Immunocytokines with activity-on-demand by combination with small molecule inhibitors
Author:
Publisher
Springer Science and Business Media LLC
Link
https://www.embopress.org/doi/epdf/10.1038/s44321-024-00047-9
Reference10 articles.
1. Dakhel S, Ongaro T, Gouyou B, Matasci M, Villa A, Neri D, Cazzamalli S (2019) Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade. Oncotarget 10(62):6678–6690
2. Gout DY, Groen LS, van Egmond M (2022) The present and future of immunocytokines for cancer treatment. Cell Mol Life Sci 79(10):509
3. Hutmacher C, Neri D (2019) Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev 141:67–91
4. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G et al (2010) The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46(16):2926–2935
5. Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C (2022) Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology 11(1):2083479
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3